P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study

Lignende værker

• Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
  af: Ogata, Misato, et al.
  Udgivet: (2020)
• A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
  af: Su, Guan-Li, et al.
  Udgivet: (2020)
• A Systematic Review and Network Meta‐Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer
  af: Sonbol, Mohamad Bassam, et al.
  Udgivet: (2019)
• P-273 Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study
  af: Hironaga, Satake, et al.
  Udgivet: (2016)
• Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
  af: Satake, Hironaga, et al.
  Udgivet: (2020)